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Abstract 
Background 
Two recent randomized trials studied the benefit of Mineralocorticoid receptor antagonists 
(MRA) in ST-elevation myocardial infarction (STEMI) irrespective or in absence of heart 
failure. The studies were both undersized to assess hard clinical endpoints. A pooled analysis 
was pre-planned by the steering committees. 
Methods  
We conducted a pre-specified meta-analysis of patient-level data of STEMI patients recruited 
in 2 multicenter superiority trials, randomized within 72 hours after symptom onset. Patients 
were allocated (1:1) to 2 MRA regimens: 1. An intravenous bolus of potassium canrenoate 
(200 mg) followed by oral spironolactone (25 mg od) versus standard therapy; or 2. Oral 
Eplerenone (25 to 50 mg) in versus placebo. The primary and key secondary outcomes, all 
cause death and the composite of all cause death or resuscitated sudden death respectively, 
were assessed in the intention to treat population using a Cox model stratified on the study 
identifier. 
Results 
Patients were randomly assigned to receive (n=1118) or not the MRA regimen (n=1123). 
After a median follow-up time of 188 days, the primary and secondary outcomes occurred in 
5(0.4%) and 17 (1.5%) patients (adjHR 0.31, 95%CI 0.11 to 0.86, p=0.03) and, 6(0.5%) and 
22(2%) patients (adjHR 0.26; 95% CI 0.10-0.65, p=0.004) in the MRA and control groups 
respectively. There were also trends toward lower rates of cardiovascular death (p=0.06) and 
ventricular fibrillation (p=0.08) in the MRA group. 
Conclusion  
Our analysis suggests that compared to standard therapy MRA regimens are associated with a 
reduction of death and death or resuscitated sudden death in STEMI. 
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What is already known about this subject? 
Mineralocorticoid receptor antagonists reduce mortality in the setting of myocardial infarction 
complicated by heart failure. 
What does this study add? 
The study shows that regardless of heart failure, mineralocorticoid receptor antagonists reduce 
mortality in the setting of ST elevation myocardial infarction, in addition to optimal 
treatment. 
How might this impact on clinical practice? 
The use of very low cost mineralocorticoid receptor antagonists may be considered in ST 
elevation myocardial infarction patients irrespective of heart failure to reduce mortality 
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Introduction 
Rationale 
High aldosterone plasma levels early after myocardial infarction are associated with mortality, 
sudden cardiac death and heart failure. [1–5] Experimental studies have shown that early 
administration of MRA after myocardial infarction could improve myocardial healing and 
both electrical and structural remodeling.[6,7] Small-sized studies have also reported a benefit 
of MRAs, initiated early after myocardial infarction in the prevention of left ventricular 
remodeling [8,9] and life-threatening arrhythmia.[10,11]  
Mineralocortoid receptor antagonists (MRA) spironolactone and eplerenone reduce mortality 
in the setting of congestive heart failure with reduced ejection fraction and myocardial 
infarction complicated by left ventricular dysfunction and heart failure.[12–14]  
The Double-Blind, Randomized, Placebo-Controlled Trial Evaluating The Safety And 
Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction 
(REMINDER) [15] showed that eplerenone used within the first 24 hours of ST-segment 
elevation MI (STEMI) excluding patients with heart failure, was safe and effective on a 
composite outcome mainly driven by the biological outcome of a lower plasma level of B-
type natriuretic peptide. More recently the Aldosterone Lethal effects Blockade in Acute 
myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival 
at Six months follow-up (ALBATROSS) failed to demonstrate a benefit of a spironolactone-
based MRA regimen in improving outcome in the general setting of STEMI or non-STEMI 
irrespective of heart failure, but suggested a potential significant reduction of rates of death by 
the MRA in the STEMI subgroup of patients (77% of the population).[16] Both 
ALBATROSS and REMINDER studies were undersized to detect a difference in rates of hard 
clinical outcomes. A pooled analysis of individual participant-level data was preplanned by 
the steering committees of the 2 trials prior to the end of the inclusion periods. 
 5 
Objectives 
The aim of this pooled analysis of patient-level data was to investigate the effect of a MRA 
regimen initiated early after the onset of STEMI, irrespective or in absence of heart failure, on 
mortality and the composite of death or resuscitated sudden death. 
Methods 
Study design and population 
Our study used pooled individual patient-level data of the STEMI subgroup of the 
ALBATROSS[16] and the total population of the REMINDER[15] randomized trials. Both 
trials studied the efficacy of an MRA regimen in addition to standard therapy in comparison 
with either standard therapy alone or associated with a placebo. The designs of the studies are 
briefly depicted in supplementary table 1. ALBATROSS- and REMINDER-eligible patients 
were men and non-pregnant women presenting with STEMI within 72 and 24 hours of 
symptom onset respectively. REMINDER included STEMI patients only while ALBATROSS 
included not only STEMI (n=1229) but also Non-STEMI patients (n=369) with a significant 
interaction between the presentation type and treatment with respect to mortality. Hence only 
STEMI patients of the ALBATROSS trial were included in the present analysis. Other 
differences between the ALBATROSS and REMINDER studies included the treatment (IV 
potassium canrenoate followed by oral spironolactone versus oral eplerenone), the timing of 
the randomization with respect to symptom onset (within 24 versus within 72 hours) and the 
duration of follow-up (182±40 versus 317±218 days). Furthermore, to be included in 
REMINDER no sign of heart failure was to be present at randomization while in 
ALBATROSS patients were included regardless of signs of heart failure. The comparison 
between the patients’ characteristics of the 2 studies is reported in supplementary table 2. 
Outcomes 
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The primary outcome of the ALBATROSS trial was the composite of death, resuscitated 
cardiac arrest, significant ventricular arrhythmia, class IA indication[17] for implantable 
defibrillator, new or worsening heart failure over the period of 6 months following 
randomization. The primary outcome of the REMINDER trial was the composite of 
cardiovascular mortality, re-hospitalization or extended initial hospital stay for heart failure or 
sustained ventricular tachycardia or ventricular fibrillation, left ventricular ejection fraction ≤ 
40% ≥1 month post- randomization or high BNP or NT-proBNP levels.[15] 
The primary efficacy outcome of the present study was mortality of any cause. As BNP was 
not measured in ALBATROSS and there were differences between definitions of events 
between the trials such as heart failure (requiring any treatment versus hospitalization or 
emergency room visit) or sustained/significant ventricular tachycardia (requiring any 
treatment versus hospitalization), any endpoint other than mortality was considered as a 
secondary endpoint. The key secondary efficacy outcome was the composite of death and 
resuscitated sudden death. Other secondary efficacy outcomes analyzed included 
cardiovascular death, resuscitated cardiac death, ventricular fibrillation, any ventricular 
arrhythmia (ventricular tachycardia or fibrillation), stroke, implanted cardiac defibrillator, 
class IA[17] indication for defibrillators-whether implanted or not- and recurrent myocardial 
infarction -study specific definitions-. An independent committee adjudicated all outcomes in 
both trials. 
Safety outcomes included Hyperkalemia > 5.5 and > 6 mmol/L at any time after 
randomization and acute renal failure defined by an increase in estimated glomerular filtration 
rate (eGFR) of ≥25% in comparison with admission eGFR. For the present analysis, eGFR 
was calculated for all patients based on Cockroft-Gault method. 
Statistical analysis 
All analyses used individual patient-level data of the pooled STEMI subgroup of the 
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ALBATROSS and the total population of the REMINDER trials. The pooled analysis of the 
two patient populations was pre-planned by the steering committees of the two trials. The full 
raw datasets were provided by the studies’ organizers and analyzed independently from the 
published data. All data were assessed within the 2 sets for completeness and coherence. No 
specific issue was observed.  
A one stage approach was used for the analysis. Data were compared between treatment arms 
using the Cochran-Mantel-Haenszel test and a 2-way ANOVA both using the study identifier 
as the stratification variable. χ2 test and Student’s t test were used for the comparison of the 
variables between the studies. 
All efficacy endpoints were analyzed as time-to-event outcomes using Cox models 
systematically stratified on the study identifier with a follow-up time of 188 days equal to the 
median follow-up time of the pooled data. Kaplan-Meier cumulative hazards curves were 
drawn for the comparison of the primary and key secondary outcomes between treatment 
groups. Safety endpoints were analyzed as binary variables compared between treatment 
groups using a Cochran-Mantel-Haenszel test stratified on the study identifier. 
Post hoc sensitivity analyses were performed for all efficacy endpoints using the Cox models 
stratified on the study identifier and adjusted on variables unequally distributed between the 
treatment arms with a p value threshold of <0.20. 
Inter-study heterogeneity assessments were performed by the measurement of the interaction 
between the study identifier and the treatment arm using a cox model for efficacy endpoints 
and a logistic regression model for safety endpoints without stratification. 
Interaction between subgroups pre-defined in the two trials and treatment was tested using the 
Cox models stratified on the study identifier when data were available for both trials.  
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All tests had a two-sided significance level of 5% and were performed using R software, 
version 3.2.3 for Mac (R foundation for statistical computation). 
Results 
A total of 2241 patients were randomly assigned to the MRA regimen (1118 patients) or 
control regimen (1123 patients). 
Despite the differences between ALBATROSS and REMINDER trials (supplementary table 
1), the active and control groups were well balanced with respect to most baseline 
characteristics and treatment strategies (Table 1) with the exception of significantly higher 
heart rate (p=0.02) and systolic blood pressure (p=0.02), as well as higher rates of Killip class 
≥ II on admission in the control group (p=0.02). The standard of care for the index event 
included fibrinolysis in 189 (8.4%), primary percutaneous coronary intervention (PCI) in 
1954 (87.2%), any PCI in 2060 (91.9%) and coronary artery bypass surgery in 41 (1.8%) 
patients. 
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Table 1. Patient characteristics according to treatment 
Variable 
Overall 
n= 2241  
Active 
n=1118 
Control 
n=1123 
p 
Age (years) 58±12 58±11 58±12 0.8 
Gender (Female) 377(16.8%) 178(15.9) 199(17.7) 0.3 
Admission characteristics         
Body mass index (Kg/m2) 27±5 27±5 27±5 0.12 
Heart rate (per minute) 73±15 73±15 74±15 0.02 
Systolic blood 
pressure(mmHg) 
124±21 123±21 125±21 0.02 
Killip class 1.05±0.28 1.03±0.22 1.06±0.33 0.007 
Killip class ≥ 2 82(3.7) 29(2.6) 53(4.7) 0.007 
Plasma creatinine (µmol/L) 81.8±22.3 82±22 81±23 0.4 
eGFR (mL/min) 104±36 102±35 105±37 0.14 
Plasma potassium (mmol/L) 4.02±0.5 4.03±0.5 4.01±0.4 0.3 
GRACE score 140±23 140±22 140±24 0.6 
Medical history      
Systemic hypertension 964(43.0) 464(41.5) 500(44.5) 0.15 
Diabetes mellitus 298(13.3) 145(13.0) 153(13.6) 0.7 
Hypercholesterolemia 883(39.4) 450(40.3) 433(38.6) 0.4 
Active smoking 772(34.5) 375(33.5) 397(35.4) 0.4 
Prior myocardial infarction 136(6.1) 71(6.4) 65(5.8) 0.6 
Prior stroke 44(2.0) 28(2.5) 16(1.4) 0.09 
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Initial/in-hospital management         
Primary PCI 1954(87.2) 971(86.9) 983(87.5) 0.7 
Any PCI 2060(91.9) 1028(91.9) 1032(91.9) 0.96 
Coronary Bypass surgery 41(1.8) 23(2.1) 18(1.6) 0.5 
Fibrinolysis 189(8.4) 96(8.6) 93(8.3) 0.8 
Glycoprotein IIBIIIA inhibitors 833(37.2) 409(36.6) 424(37.8) 0.6 
Aspirin 2201(98.2) 1096(98.0) 1105(98.4) 0.6 
Clopidogrel 1445(64.5) 734(65.7) 711(63.3) 0.3 
Prasugrel 1273(56.8) 619(55.4) 654(58.2) 0.2 
Ticagrelor 28(1.3) 13(1.2) 15(1.3) 0.9 
Any p2y12 inhibitor 2225(99.3) 1110(99.3) 1115(99.3) 1.0 
ACEi or ARB 1964(87.6) 975(87.2) 989(88.1) 0.6 
Beta-blockers 2077(92.7) 1037(92.8) 1040(92.6) 0.95 
Diuretics 293(13.1) 135(12.1) 158(14.1) 0.2 
Statins 2171(96.9) 1076(96.2) 1095(97.5) 0.11 
LVEF* 53±9 53±9 53±9 0.2 
Follow-up duration (days) 243±164 244±165 241±163 0.7 
Data are n(%) or mean±SD. LVEF : left ventricular ejection fraction (*available in 2014 
patients only) ; eGFR : estimated glomerular filtration rate (Cockroft-Gault method) ; 
PCI : percutaneous coronary intervention, ACEi : angiotensin converting enzyme 
inhibitor, ARB : angiotensin receptor antagonist 
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As reported in table 2, after a median follow-up of 188 days (interquartile range 52 days), the 
primary outcome (Figure 1) occurred in 5 (0.4 %) and 17 (1.5%) patients in the active and 
control groups, respectively (HR 0.30, 95% CI 0.11-0.81); p=0.01 and adjusted-HR 0.31, 
95% CI 0.11-0.86; p=0.03). Two un-adjudicated deaths reported as security events 389 and 
528 days after randomization in the control and the active groups of the REMINDER trial 
respectively were not included in the analysis. All resuscitated sudden deaths were reported 
within the analysis time. The key secondary outcome of death or resuscitated sudden death 
(Figure 2) occurred in 6 (0.5 %) and 22 (2%) patients in the active and control groups, 
respectively (HR 0.27, 95% CI 0.11-0.67; p= 0.002 and adjusted-HR 0.26, 95% CI 0.10-0.65; 
p=0.004). There were also trends toward lower rates of death from cardiovascular causes 
(p=0.06) and ventricular fibrillation (p=0.08 and adjusted-HR) in the active group. Other 
assessed efficacy endpoints did not differ between the two groups. The two trials were 
different with respect to the rates of the primary and secondary key outcomes as well as 
several other outcomes (supplementary table 3). However with the exception of a trend 
(p=0.06) towards a heterogeneity in rates of recurrent myocardial infarction, no significant 
inter-study heterogeneity was detected.
 Table 2. Outcomes according to treatment arm 
 n (%) Active versus control 
Inter-study 
heterogeneity 
 
Active 
n=1118 
Control 
n=1123 
HR (95% CI) p Adj-HR (95% CI) p p for interaction 
Death 5 (0.4) 17 (1.5) 0.30 (0.11-0.81) 0.01 0.31 (0.11-0.86) 0.03 0.2 
Death/resuscitated sudden death 6 (0.5) 22 (2) 0.27 (0.11-0.67) 0.002 0.26 (0.10-0.65) 0.004 0.6 
Sudden cardiac death 3 (0.3) 3 (0.3) 1.15 (0.23-5.77) 0.9 0.84 (0.15-4.59) 0.8 1 
Cardiovascular death 5 (0.4) 13 (1.2) 0.38 (0.14-1.07) 0.06 0.38 (0.13-1.12) 0.08 0.1 
Resuscitated sudden death 1 (0.1) 5 (0.4) 0.20 (0.02-1.70) 0.1 0.21 (0.02-1.82) 0.2 1 
Major ventricular arrhythmia 43 (3.8) 49 (4.4) 1.10 (0.73-1.66) 0.7 1.15 (0.76-1.74) 0.5 0.3 
Ventricular fibrillation 1 (0.1) 6 (0.5) 0.18 (0.02-1.54) 0.08 0.18 (0.02-1.55) 0.1 1 
Ventricular tachycardia 42 (3.8) 43 (3.8) 1.24 (0.81-1.91) 0.3 1.30 (0.84-2.00) 0.2 0.99 
Heart failure 45 (4) 51 (4.5) 1.03 (0.69-1.55) 0.9 0.89 (0.59-1.35) 0.6 0.2 
 13 
ALBATROSS primary outcome* 104 (9.3) 121 (10.8) 0.91 (0.70-1.19) 0.5 0.93 (0.71-1.21) 0.6 0.2 
Implanted ICD 5 (0.5) 7 (0.6) 0.84 (0.27-2.65) 0.76 0.64 (0.19-2.12) 0.5 01 
Indication for ICD 25 (2.2) 35 (3.1) 0.74 (0.44-1.24) 0.3 0.76 (0.45-1.28) 0.5 0.6 
Recurrent myocardial infarction 12 (1.1) 11 (1) 1.17 (0.51-2.66) 0.7 1.24 (0.54-2.82) 0.6 0.1 
Stroke 5 (0.4) 5 (0.4) 1.09 (0.31-3.81) 0.7 1.04 (0.30-3.63) 0.7 0.9 
Death or heart failure 47 (4.2) 60 (5.3) 0.9 (0.61-1.32) 0.6 0.78 (0.53-1.16) 0.2 0.3 
Safety outcomes   OR (95% CI) p    
Acute renal failure 26 (2.3) 18 (1.6) 2.02 (0.91-4.53) 0.1 - - 0.7 
Hyperkalemia 
>5.5 mmol/L 
>6 mmol/L 
 
37 (3.3) 
11 (1) 
 
20 (1.8) 
4 (0.4) 
 
1.89 (1.09-3.29) 
2.77 (0.88-8.74) 
 
0.03 
0.1 
 
- 
- 
 
- 
- 
 
0.09 
0.04 
*The composite of death, resuscitated sudden death, ventricular arrhythmia, heart failure and indication for ICD. Adj-HR: HR adjusted on variable 
unequally distributed between treatment arms with a threshold p value <0.2 –i.e. baseline binary killip class, heart rate, systolic blood pressure, 
eGFR, body mass index and, history of systemic hypertension and stroke. 
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The results were consistent among all subgroups with respect to the primary and secondary key 
outcomes (supplemantry Figure). HR could not be calculated in the patient subgroups with a Killip 
class ≥2 in the active arms, as well as all patients with a grace score <109 because of absence of any 
primary or secondary key outcome. HR could also not be calculated for death in patients <65 because 
of absence of event in the active arm.  
Hyperkalemia > 5·5 mmol/L occurred in 37 (3.3%) and 20 (1.8%) patients in the active and control 
groups, respectively (stratified OR 1.89; 95% CI, 1.09 to 3.29, p=0.03) while rates of Hyperkalemia > 
6 mmol/L and acute renal failure were not significantly different between the two groups. A trend 
toward (p=0.09) and a significant inter-study heterogeneity (p=0.04) were detected with respect to the 
hyperkalemia >5.5 and 6 outcomes. 
Discussion  
Our analysis based on the pooled patient-level data of the two recent randomized trials addressing the 
question of early MRA blockade in low risk STEMI shows reduced rates of death compared to 
standard therapy. Although the subgroup analysis should be considered as only exploratory, it suggests 
a consistent effect of the treatment. MRA blockade appears to be associated with reduced risks of all-
cause mortality and the composite of death or resuscitated sudden cardiac death. However the analysis 
failed to show a benefit with respect to other endpoints including heart failure or ventricular 
arrhythmia. Rates of hyperkalemia > 5.5 mmol/L were significantly higher among patients treated with 
MRA. 
Experimental studies have shown that the early use of MRA after MI reduces left ventricular 
expansion and extensive fibrosis by antagonizing activation of the mineralocorticoid receptor by 
aldosterone and cortisol.[18–20] The clinical benefit of MRA have been extensively demonstrated in 
heart failure irrespective of its ischemic or non-ischemic origin. [12,13] MRA use is also associated 
with a reduction of mortality in patients with heart failure and reduced systolic ventricular function 
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after myocardial infarction.[14] Thus, the addition of MRAs to beta-blockers and angiotensin 
converting enzyme inhibitors has been highly recommended [21–23] in patients with heart failure and 
reduced left ventricular function irrespective of the etiology of heart failure. 
In the Eplerenone Post Acute MI Heart Failure Efficacy and Survival Study (EPHESUS) 15 eplerenone 
was initiated 3 to 14 days after the onset of MI complicated by heart failure and reduced left 
ventricular function. The benefit observed was apparently driven by the group of patients treated 
earlier (i.e. 3-7 days).[24] This finding is consistent with other studies reporting high aldosterone 
plasma levels early after MI[25,26] and the relationship of these levels with clinical outcomes.[1–3] 
The REMINDER study recruited low risk STEMI patients with no heart failure at admission and very 
low mortality rates. Although REMINDER showed a benefit of eplerenone over placebo, the benefit 
was driven by the B-type natriuretic peptide levels with only non-significant trends on clinical 
outcomes.[15] The ALBATROSS trial recruited a broader STEMI population at higher risk as 
compared with REMINDER. ALBATROSS STEMI population included all-comers presenting for 
primary PCI, few with heart failure (6.7%), with significantly higher admission GRACE scores but 
also more contemporary and optimal treatment as compared to REMINDER. Although the study failed 
to show the benefit of MRAs on the primary outcome it highlighted a significant signal in favor of a 
MRA effect on mortality in STEMI. The present pooled analysis includes a relatively young and low-
to-intermediate risk STEMI population (mean grace score 140) treated optimally with very high rates 
of revascularization and optimal medical therapy. The mortality reduction with MRAs in addition to an 
optimal management in such a low risk population should not be neglected. The previously mentioned 
pre-clinical and clinical data, the reduction of mortality in the setting of chronic heart failure or post 
myocardial infarction heart failure as well as the strength of the association support the plausibility of 
a MRA effect on mortality in the setting of STEMI. The early blunting of biological effects of MR 
activation after acute coronary artery occlusion[7,6,19], may lead to a favorable effect in STEMI 
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through the un-triggering of the neurohormonal activation and the subsequent post-MI fibrosis and 
remodeling both leading to higher risk of death. 
A recently published study-level meta-analysis of eleven randomized trials showed also the benefit of 
MRAs on mortality [27]. The study included STEMI and non-STEMI patients, with heart failure as an 
inclusion criteria or not. However the benefit of the MRAs was driven by studies that included patients 
with heart failure. Compared to the latter study, our patient-level analysis pooling only STEMI 
patients, without heart failure as an inclusion criteria and with a more adequate univariable and 
adjusted analysis of censored data may be considered as more sensitive in detecting differences 
between groups. 
Interestingly, the MRA-related reduction of mortality found in our study was not associated with a 
concordant significant reduction of major ventricular arrhythmia or heart failure, although both events 
occurred numerically less in the active treatment group. 
Sustained ventricular tachycardia or fibrillation have been reported to occur in 5.2% of patients after 
primary PCI essentially in the 48 first hours in the relatively recent analysis of the Harmonizing 
Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (Horizons-AMI) 
randomized trial.[28] In the latter study, such events did not portend decreased survival. The rates of 
ventricular tachycardia or fibrillation were approximately 4% in the pooled population of our analysis, 
with a difference between rates in the ALBATROSS (7.2%) and the REMINDER trials (0.4%). Such a 
difference is likely to be due to the difference of the definitions of ventricular tachycardia (requiring 
hospitalization) in REMINDER but also due to a more selected patient population without heart failure 
at admission, with preserved ejection fraction and with extremely low event rates – i.e death, heart 
failure, indication for ICD-. The absence of effect on rates of ventricular arrhythmia in our study is not 
in contradiction with a possible MRA effect on mortality. Concordant with our study, in both 
Randomized Aldosterone Evaluation Study (RALES)[12] and EPHESUS[14] trials mortality was 
reduced with MRA despite the absence of effect on the rates of ventricular arrhythmia. Moreover, in 
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concordance with the above-mentioned study[28] most ventricular tachycardia were reported within 
only 48hours after randomization and such events may not impact mortality. Finally ventricular 
arrhythmia suppression after myocardial infarction is known not to improve survival.[29] Considering 
the trend towards a reduction of rates of ventricular fibrillation but not ventricular tachycardia in our 
analysis, it is plausible that MRAs may reduce the rates of lethal arrhythmia, or prevent the fatal issue 
of arrhythmia without affecting the frequency of post-STEMI arrhythmia in general. 
The global rate of hospitalization for heart failure (4.4%) in a recent multicenter real-life cohort of 
STEMI patients undergoing primary PCI [30] was higher than in REMINDER (1.4%) but lower than 
in ALBATROSS (6.3%). The differences in study definitions, the low-risk populations and the short 
durations of follow-up could explain the absence of detectable MRA effect on heart failure in the 
current analysis. 
Our analysis also highlights the relative safety of the MRA regimens used in the studies. Although the 
rates of hyperkalemia >5.5 mmol/L were higher in the MRA group than in the control group, they 
remained lower than what has been previously reported[14,15] and the rates of hyperkalemia >6 
mmol/L and acute renal failure were not different between treatment groups. However the results on 
hyperkalemia should be considered with great precaution because of a significant inter-study 
heterogeneity. 
Our analysis has limitations inherent to its design pooling data from different studies with different 
designs and different active treatments. However a class effect is very likely between the drugs and the 
stratified and adjusted analyses as well as absence of detected inter-study heterogeneity may minimize 
the risk of bias. Furthermore event rates remained low and event definitions were different for 
ventricular tachycardia and heart failure. Nevertheless with respect to the primary and the key 
secondary outcomes of our study -death and death or resuscitated sudden death- the analysis may be 
considered as robust. The adjusted analysis should be interpreted with the consideration of low event 
rates, especially with respect to mortality. However the similar magnitude of effects and their 
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confidence intervals between the un-adjusted and adjusted analyses supports the robustness of the 
findings. The subgroup analysis should be considered with great precaution because of the risk of 
multiple testing with low event rates. Whether the benefit of MRA may interact with the infarct 
location or the culprit vessel could not be assessed by our study because of lack of data. 
Although the present report is the largest experience in STEMI outside of the scope of heart failure, it 
may lack power to detect differences between several studied outcomes. Larger and specifically 
designed studies are needed to assess such outcomes. 
Conclusions 
Our analysis based on pooled patient-level data from two randomized trials suggests a significant 
reduction of death and death or resuscitated sudden death associated with MRA regimens given early 
after low risk STEMI. Despite strong recommendations based on robust clinical evidence in the setting 
of heart failure, MRAs are still underused in routine clinical practice. Our data on both efficacy and 
safety of MRAs may contribute to extend the use of these life-saving and low-cost drugs. Although our 
study seems robust with respect to its primary outcome, the low event rates highlight the need for more 
studies adequately sized and specifically designed to confirm the potentially major clinical benefit 
associated with low-cost treatments. 
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Glossary 
ALBATROSS : Aldosterone Lethal effects Blockade in Acute myocardial infarction Treated with or 
without Reperfusion to improve Outcome and Survival at Six months follow-up. Clinical trial 
registration: NCT01176968 
REMINDER : A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating The Safety And 
Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction. Clinical 
trial registration:NCT01176968 
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Figure Legends 
Figure 1.· Kaplan-Meier cumulative hazard curves for death 
Figure 2. Kaplan-Meier cumulative hazard curves for death or resuscitated sudden death 
Supplementary Figure. Subgroup analysis 
A. Death 
B. Death or Resuscitated Sudden Death 
ACEi: angiotensin conversion enzyme inhibitor; ARB: angiotensin receptor ablockers, PCI: 
percutaneous coronary intervention, LVEF: left ventricular ejection fraction; eGFR: estimated 
glomerular filtration rate; BMI: body mass index 
 
